en
E-mail us
(925) 558-5040
bd_global@crystalpharmatech.com
 cn
cn
Knowledge Hub Explore
Conquering the “Uncrystallizable”: Advanced Strategies for PROTAC Solid-Form Development Blog Conquering the “Uncrystallizable”: Advanced Strategies for PROTAC Solid-Form Development
The “Double-Limited” Challenge: Is ASD Always the Answer? Blog The “Double-Limited” Challenge: Is ASD Always the Answer?
Predicting Physical Stability of Amorphous Solid Dispersions (ASD) Whitepaper Predicting Physical Stability of Amorphous Solid Dispersions (ASD)
Webinar Series Explore
Solid Form Landscape to Formulation Strategy: The Role of Computational Screening and Risk Assessment Crystal Pharmatech Formulation Forum Solid Form Landscape to Formulation Strategy: The Role of Computational Screening and Risk Assessment
Applying PBPK and PBBM Across R&D: From Early Insights to Formulation Crystal Pharmatech Formulation Forum Applying PBPK and PBBM Across R&D: From Early Insights to Formulation
Patient-Centered Controlled and Modified Release Drug Delivery: Formulation & Process Development Crystal Pharmatech Formulation Forum Patient-Centered Controlled and Modified Release Drug Delivery: Formulation & Process Development
Events Explore
Conference
Events
Conference
10 Mar 2026
Events
Networking
10 Mar 2026
News Explore
Patients can’t carry a fridge around: research meets the real world
News
Patients can’t carry a fridge around: research meets the real world
20 Mar 2026
Crystal Pharmatech | Reflecting on 2025
21 Feb 2026
Technical Guideline for the Study of Polymorphism of Innovative Chemical Drugs by National Medical Products Administration (NMPA)
28 Jan 2026
Brise Pharma Presents“Best Partner”Trophy to Crystal Formulation Services, Recognizing Their Excellence in Drug Product CDMO Services
04 Dec 2025
Small Molecule
First-Time-Right 3-STEP Approach Developability Assessment API Form and Solid-State Research Crystallization Development Services Pre-formulation Studies Analytical Research and Quality Control Formulation Development Clinical and Commercial GMP Manufacturing Clinical Supply
Crystal Bio Solutions
Biologics Characterization and CMC Analytics Bioanalytical and Biomarker Services Quantitative Clinical Pharmacology (QCP)
Crystal NAX
DNA Synthesis RNA Synthesis LNP Formulation Services Analytical & Characterization Services Early-Phase Manufacturing Catalogue Products
Platforms
Solid Form Screening Solid Form Developability Evaluation Absolute Structure Determination Crystallization Process Development Conventional Oral Solid Dosage Forms Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides Mini-tablet
Quick Links
Highlights News Events Knowledge Hub Webinar Series
Contact Us
bd_global@crystalpharmatech.com (925) 558-5040
U.S
NJ Sites: Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey, USA 08512

2005 Eastpark Blvd, Cranbury, New Jersey, USA 08512

CA Site: 7133 Koll Center Parkway, Suite 200, Pleasanton, California, USA 94566
Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
China
No. 288, Jiangyun Road, Suzhou Industrial Park, Suzhou, China 215123

Floor 1, Bldg. 3, 68 Chunpu Road, Suzhou Industrial Park, Suzhou, China 215123
Subscribe to be the first to get the updates!

Subscribe to be the first to get the updates!

Privacy Policy
Sitemap
Small Molecule
First-Time-Right 3-STEP Approach Developability Assessment API Form and Solid-State Research Crystallization Development Services Pre-formulation Studies Analytical Research and Quality Control Formulation Development Clinical and Commercial GMP Manufacturing Clinical Supply
Crystal Bio Solutions
Biologics Characterization and CMC Analytics Bioanalytical and Biomarker Services Quantitative Clinical Pharmacology (QCP)
Platforms
Quick Links
About Us Events
NJ Sites: Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey, USA 08512

2005 Eastpark Blvd, Cranbury, New Jersey, USA 08512

CA Site: 7133 Koll Center Parkway, Suite 200, Pleasanton, California, USA 94566
bd_global@crystalpharmatech.com (925) 558-5040
Privacy Policy
Sitemap